AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05928247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competing Items and Response Blocking
Description: The investigators will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. The investigators will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. The investigators will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.
Study NCT05928247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research Units in Behavioral Intervention (RUBI) protocol
Description: Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
Study NCT05133180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxervate
Description: Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).
Study NCT05133180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle will be instilled with the same scheme of the test product
Study NCT04790526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercises Dose
Description: Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
Study NCT06154083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin-delta (Rekovelle) 20 mcg/day from D1
Description: On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
Study NCT06154083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin-delta (Rekovelle) 15 mcg/day from D1
Description: On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
Study NCT05631964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion
Study NCT06254807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-0525
Description: Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor
Study NCT06087640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aQIV or aTIV
Description: Participants receive a 0.5-mL intramuscular dose of aQIV or aTIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg of hemagglutinin (HA) of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 µg HA). A 0.5 mL dose of aTIV contains nominally 15 µg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 µg HA). The strain composition of aQIV and aTIV is that recommended by the World Health Organization (WHO) for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
Study NCT06087640 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QIV or TIV
Description: Participants receive a 0.5-mL intramuscular dose of the non-adjuvanted QIV or TIV on Day 1. A 0.5 mL dose of QIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 μg HA). A 0.5 mL dose of TIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 μg HA). The strain composition of QIV and TIV is that recommended by the WHO for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
Study NCT05091437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observational study
Description: Incidental lung nodules identification
Study NCT06353516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: delivered via intravenous route
Study NCT06353516 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane
Description: delivered via inhalation route
Study NCT05214950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORI monitoring
Description: Oxygen reserve index monitoring during the surgery
Study NCT04797728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
Study NCT05537857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary salt
Description: Controlled feeding study that varies in salt content.
Study NCT05280158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Moderna COVID-19 vaccine)
Description: Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
Study NCT05280158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273 (Moderna COVID-19 vaccine)
Description: Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
Study NCT05263882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine combined with eribulin
Description: * Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur.
Study NCT04403737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rothman Index
Description: The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
Study NCT04787120 — intervention group
Intervention type: DEVICE
Intervention: SQUIDperi
Description: Liquid embolic delivery syringes and micro-catheter
Study NCT05569824 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lateral-flow Device
Description: An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
Study NCT05189509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNK-Tissue Plasminogen Activator
Description: 0.25 mg TNK thrombolysis
Study NCT05189509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNK-Tissue Plasminogen Activator
Description: 0.25 mg TNK thrombolysis
Study NCT04142814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-PEP
Description: First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist.
Study NCT04142814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
Study NCT05109377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endocan
Description: Endocan will measured before and after treatment
Study NCT05109377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tadalafil
Description: tadalafil
Study NCT04987554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glycophosphopeptical AM3
Description: 3 g/day of AM3
Study NCT04987554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 g/day of placebo
Study NCT06470425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy group
Description: Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
Study NCT06470425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Guided group
Description: Participants receive supplement prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study NCT06027983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric receptor T-cells + Trastuzumab
Description: Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
Study NCT06027983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Cyclophosphosphamide
Description: 3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
Study NCT06092502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
Study NCT06092502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy Program
Description: This protocol included stretching and strengthening exercises
Study NCT06092502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physiotherapy Program
Description: This protocol included stretching and strengthening exercises
Study NCT06656312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use ASUS EndoAim as an assistant software to perform colonoscopy
Description: Use ASUS EndoAim as an assistant software to perform colonoscopy
Study NCT06664619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp/ABS
Description: Inhalation powder
Study NCT06664619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP
Description: Inhalation powder
Study NCT06664619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABS
Description: Inhalation powder
Study NCT06664619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder
Study NCT05611697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single anastomosis sleeve ileal bypass
Description: The abdominal cavity is entered directly (visual trocar) with or without the use of Verres needle. A 6-port set up and a liver retractor is utilized. A sleeve gastrectomy is performed as described below, but division of the stomach starts 6 cm proximal to the pylorus. The small bowel is measured 300cm from the ileocecal valve, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 3.0 cm of 45 mm stapler is used the anastomosis; completed with a 2-0 PDS running suture. The biliopancreatic limb is anchored to the sleeve 4 cm proximal to the anastomosis (non-resorbable V-loc 3-0). Fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
Study NCT05611697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: In the laparoscopic sleeve gastrectomy, the abdominal cavity is entered directly with a visual trocar with or without the use of Verres needle. The set up includes a total of 5 ports. The Natanson liver retractor is utilized. The greater omentum is separated from the major side of the stomach from the pylorus to the angle of His. The left crus is visualized and the hiatus is inspected for the presence of hernia. A 36 French bougie is introduced and the stomach is divided along this from 4-5cm proximal to the pylorus to 1cm lateral to the angle of His using two purple cartridges (Medtronic Tri-Staple™ technology) followed by beige 60mm cartridges to the angle of His, 1 cm lateral to the esophagus. The sleeve is tested for leaks with instillation of 50ml methylene blue in the tube. The fascia defect is closed with suture for the port site where the specimen is extracted.
Study NCT04868240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent training program
Description: The experimental group will perform 16-weeks of exercise. The exercise sessions will occur three times/week.~The participants should conduct their daily activities as usual outside of the study and maintain the same diet.
Study NCT05581719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
Study NCT05581719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)
Study NCT05581719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Immune checkpoint inhibitor (anti-PD-1 antibody)
Study NCT05735145 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel combined with platinum
Description: Adjuvant chemotherapy with paclitaxel combined with platinum
Study NCT05735145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel combined with platinum
Description: Adjuvant chemotherapy with paclitaxel combined with platinum
Study NCT05438550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day high-dose Tegoprazan Dual Therapy (HDDT)
Description: 14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
Study NCT05438550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day high-dose Tegoprazan Dual Therapy (HDDT)
Description: 14-day Tegoprazan high-dose dual therapy (HDDT) Tegoprazan（Luo Xin Pharmaceutical Group Co. LTD）50mg bid Amoxicillin (Amoxicillin, United Laboratories Co. LTD) 750mg qid To investigate the efficacy of high-dose dual therapy of Tegoprazan, a novel p-CAB acid suppressant, combined with amoxicillin for the eradication of Helicobacter pylori
Study NCT05738252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Frailty Scale
Description: A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
Study NCT05738252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Phenotype
Description: Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
Study NCT05945758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable resin composite technique.
Description: A metal impression tray was filled with transparent vinyl polysiloxane (EXACLEAR, GC) and used to copy the stone model with the wax-up. Then, the replica will be separated from metal tray and a needle-shaped bur will be used to drill holes through the silicone key ending in the middle of the incisal edge. It will be checked whether the holes were large enough to enable the tip of the composite syringe to pass easily and completely. Neighbouring teeth (mesial and distal one) isolated using Teflon tape, as each tooth will individually be restored for establishment of satisfactory contact points. Following etching and rinsing, the tooth dried, and a dental cord (Ultrampak, Ultradent) will be packed into sulcus for mechanical prevention of subgingival composite flow. Then, the transparent silicone index will be placed in the correct intraoral position, and a syringe filled with flowable composite will be inserted through the hole on the incisal edge.
Study NCT05945758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional layering technique
Description: the palatal surface will be restored by enamel shade; adapted on the index in the spacing area then The Unica matrix (Polydentia) will be used to restore the proximal wall, and to achieve a good seal with the palatal wall. The matrix can be stabilized with a wedge if necessary. Building the proximal wall using the enamel shade, and the incisal halo by using a dentin shade, the frame to layer the core of the restoration will be ready.
Study NCT06244251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TU-LESS
Description: TU-LESS group will receive TU-LESS for myomectomy; MPLS group will receive MPLS for myomectomy
Study NCT06244251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MPLS
Description: Patients with uterine who plan to receive MPLS for myomectomy
Study NCT04956965 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac electro-mapping
Description: Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
Study NCT04956965 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac electro-mapping
Description: Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.
Study NCT05874297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT05874297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Access to enhanced Cook for your life website
Study NCT05874297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05874297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06049277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan techniques with manual traction
Description: group A will be treated with Mulligan techniques with manual traction.16 patients in group A will be treated with Mulligan Techniques SNAGS in sitting, standing and prone position by applying Antero cranial glide in the direction of treatment plane over the spinous or transverse process and Spinal mobilization with leg movement at 6 to 8 repetitions per sessions and spinal mobilization with leg movement will be performed in side lying, patient facing the physiotherapist while the leg movement may assisted by another person (Physiotherapist/assistant). Sustained transverse glide is given on the desired spinous process with 10 repetitions of offending movement in first session while 10 reps in each of 3 sets in further sessions.
Study NCT06049277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McKenzie extension exercises with manual traction
Description: group B will be treated McKenzie extension exercises with manual traction.16 patients in group B will be treated with McKenzie active EEP in prone position with repeated movements along with standard protocols. McKenzie Extension Exercises performed actively in prone position. Extension exercises performed in three stages, initially patient instructed to be just lift the neck and look on front at the eye level, then progressed next and weight bearing on the elbow by lifting up the shoulder and then moved on third and final steps in which complete trunk extension is performed and weight bearing is on the hands.